BioCentury
ARTICLE | Strategy

Venture portfolio balancing

June 7, 2004 7:00 AM UTC

Discussions with a cross section of VCs indicate that no matter how much they differ on the value of the de-risked model, the majority pursue some kind of balanced portfolio approach that includes the full range of ideas from de novo biology to de-risked models. The difference is in how the portfolio is weighted.

Some VCs have always invested heavily in the de-risked model. Mike Powell of Sofinnova Ventures estimates that three-quarters of his life science investments start downstream from de novo discovery. They include spinouts, companies based on physician-started INDs and companies based on clever ways of using existing drugs for new indications. The fund has been investing in this way since 1997...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article